Key result
Thrombophilia during pregnancy is associated with an increased risk of placental vascular complications, with accumulating data suggesting potential benefits from maternal antithrombotic prophylaxis.
Why the study?
Does maternal antithrombotic prophylaxis improve gestational outcomes in pregnant women with thrombophilia?
Does maternal antithrombotic prophylaxis improve gestational outcomes in pregnant women with thrombophilia?
Thrombophilia in pregnancy increases the risk of vascular complications, and ongoing trials will determine if antithrombotic prophylaxis optimizes maternal and neonatal outcomes.
Should not yet change practice for antithrombotic prophylaxis in thrombophilic pregnancy; leaves open outcome benefit pending randomized trials.
Thrombophilic risk factors are common and can be found in 15% to 25% of Caucasian populations. Since pregnancy is an acquired hypercoagulable state, women harboring thrombophilia may present with clinical symptoms of vascular complications for the first time during gestation or at the postpartum period(1). Women with thrombophilia may have an increased risk of placental vascular complications, including pregnancy loss, preeclampsia, intrauterine growth restriction,and placental abruption. Accumulating data suggest that maternal antithrombotic prophylaxis may result in improved gestational outcome. Randomized trials are under way and hopefully will optimize maternal and neonatal outcome.
No takes yet. Share an insight, caveat, or question.
Benjamin Brenner (2006) conducted a review in Pregnancy complications in women with thrombophilia. Thrombophilia was evaluated. Thrombophilia during pregnancy is associated with an increased risk of placental vascular complications, with accumulating data suggesting potential benefits from maternal antithrombotic prophylaxis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: